Botox

(redirected from onabotulinum toxin A)
Also found in: Dictionary, Thesaurus, Medical.

Botox

™ a preparation of botulinum toxin used to treat muscle spasm and to remove wrinkles
Collins Discovery Encyclopedia, 1st edition © HarperCollins Publishers 2005
References in periodicals archive ?
After a median 4 (IQR 3-5) weeks post intravesical onabotulinum toxin A, most patients felt that their neurogenic bladder symptoms improved overall, and within each of the three domains of the NBSS.
The magnitude of change in the scores of the 16/21 patients who reported improvement after intravesical onabotulinum toxin A was statistically significant, and as expected, the incontinence domain showed a large magnitude of change (improving by almost a third of the possible subscale range), as did the urinary QOL question (improving by over 40% of the potential answer range).
Intradetrusor injection of onabotulinum toxin A was initially approved for the management of detrusor overactivity of neurogenic etiology.
The use of onabotulinum toxin A requires an understanding of its mechanism of action, proper injection technique, and careful counseling regarding efficacy and potential adverse effects.
There are currently three different commercial forms of botulinum toxin A available: onabotulinum toxin A (Botox[R], Allergan), abobotulinum toxin A (Dysport[R], Ispen Biopharm, Ltd.), and incobotulinum toxin A (Xeomin[R], Merz Aesthetics).
(2000) initially described onabotulinum toxin A as a treatment option in patients with spinal cord injury with detrusor overactivity.
A long-term extension study involving patients with OAB and urinary incontinence (UI) who were inadequately managed by an anticholinergic (ACH) demonstrated that onabotulinum toxin A 1 00U provides consistent, long-term improvement of OAB symptoms.
After onabotulinum toxin A treatments 1-6, QOL improvements were consistently maintained at 2-3X MID across treatment cycles, with most patients achieving [greater than or equal to]MID (range 65.2-76.1%).
Conclusions: Consistent improvements in OAB symptoms after long-term treatment with onabotulinum toxin A corresponded with durable QOL improvements, with no new safety signals.
Network meta-analysis to assess the treatment effect of onabotulinum toxin A, mirabegron, and anticholinergics vs.